Last Updated: 07 Nov 2024
Executive Summary
Boston Scientific Corp. (BSX) is a leading manufacturer of medical devices with a market capitalization of $126.07 billion. The company's strong financial performance, including an EBITDA of $4.06 billion, is driven by its focus on innovative medical technologies. Despite a recent decline in quarterly earnings growth, BSX continues to show revenue growth and has a positive analyst outlook.
Company Overview
Boston Scientific is a global company headquartered in Marlborough, Massachusetts. It operates in various medical specialties, including interventional radiology, cardiology, endoscopy, and urology. The company's products include stents, catheters, and surgical instruments.
Fundamental Analysis
Revenue: BSX reported revenue of $15.91 billion in the trailing twelve months, representing a 0.193% increase year-over-year.
Earnings: Diluted EPS for the TTM was $1.22, with a quarterly growth rate of -0.065%.
Profitability: The company has a profit margin of 0.113 and an operating margin of 0.171.
Valuation: BSX is trading at a trailing PE ratio of 70.11, a forward PE ratio of 30.58, and a price-to-sales ratio of 7.92.
Technical Analysis
Trend: BSX is currently trading above its 50-day moving average of $84.05 and its 200-day moving average of $74.74.
Support and Resistance: Support levels are seen at $80.00 and $75.00, while resistance levels are at $90.00 and $95.00.
Momentum: The relative strength index (RSI) is currently at 52, indicating a neutral momentum.
Short Term Outlook
In the short term, BSX may face some challenges due to the recent decline in earnings growth. However, the company's strong fundamentals and analyst support suggest that the stock could continue to trade within its current range.
Long Term Outlook
The long-term outlook for BSX is positive. The company's focus on innovation and its strong market position in the medical device industry should support continued growth in the coming years.
Analyst Recommendations
Analysts are generally bullish on BSX. Out of 34 analysts, 12 have a "Strong Buy" rating, 19 have a "Buy" rating, 3 have a "Hold" rating, and none have a "Sell" or "Strong Sell" rating. The average analyst target price for BSX is $97.09.
